Objective To examine the feasibility of using cross-sectional PET to identify cognitive
decliners among β-amyloid (Aβ)-negative cognitively normal (CN) elderly adults. Methods …

Objective Deposition of amyloid β (Aβ)‐containing plaques as evidenced by amyloid
imaging and cerebrospinal fluid (CSF) Aβ1–42 (Aβ42) is an early indicator of preclinical …

Molecular imaging techniques using 18 F-fluorodeoxyglucose, amyloid tracers, and, more
recently, tau ligands have taken dementia research by storm and undoubtedly improved our …

Introduction Structural magnetic resonance imaging is a marker of gray matter health and
decline that is sensitive to impaired cognition and Alzheimer's disease pathology. Prior work …

Background: Evidence suggests that the concordance between amyloid-PET and
cerebrospinal fluid (CSF) amyloid-ß (Aß) increases when the CSF Aß1–42/Aß1–40 ratio is …

Background Alzheimer's disease (AD)-related tauopathy can be measured with CSF
phosphorylated tau (pTau) and tau PET. We aim to investigate the associations between …

Background With the shift of research focus towards the pre-dementia stage of Alzheimer's
disease (AD), there is an urgent need for reliable, non-invasive biomarkers to predict …

Abstract Introduction T1‐and T2‐weighted sequences from MRI often provide useful
complementary information about tissue properties. Leukoaraiosis results in signal …

A blood-based assessment of preclinical disease would have huge potential in the
enrichment of participants for Alzheimer's disease (AD) therapeutic trials. In this study …

At the center of Alzheimer's disease pathogenesis is the aberrant aggregation of amyloid-β
(Aβ) into oligomers, fibrils and plaques. Effective monitoring of Aβ deposition directly in …